Projecting future drug expenditures-2011

被引:30
作者
Doloresco, Fred [1 ,2 ]
Fominaya, Cory [1 ]
Schumock, Glen T. [3 ,4 ]
Vermeulen, Lee C. [5 ,6 ]
Matusiak, Linda [7 ]
Hunkler, Robert J. [7 ]
Shah, Nilay D. [8 ]
Hoffman, James M. [9 ,10 ]
机构
[1] SUNY Buffalo, Dept Pharm Practice, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14260 USA
[2] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL USA
[4] Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Chicago, IL USA
[5] Univ Wisconsin Hlth, Ctr Clin Knowledge Management, Madison, WI USA
[6] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
[7] IMS Hlth, Plymouth Meeting, PA USA
[8] Mayo Clin, Div Hlth Care Policy & Res, Coll Med, Rochester, MN USA
[9] St Jude Childrens Res Hosp, Dept Pharmaceut, Memphis, TN 38105 USA
[10] Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Memphis, TN 38163 USA
关键词
Ambulatory care; Costs; Drugs; Economics; Health care; Hospitals; Prescriptions; Product development; United States;
D O I
10.2146/ajhp100712
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. Drug expenditure trends in 2009 and 2010, projected drug expenditures for 2011, and factors likely to influence drug expenditures are discussed. Summary. Various factors are likely to influence drug expenditures in 2011, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, and biosimilars. Two distinct patterns of drug expenditures continue to exist. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction of generic medications for high-cost, frequently used medications and the influence of the economic downturn. The second pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting. The influence of health care reform, the economy, and the emergence of biosimilars will be important trends to follow over the next several years, but they are unlikely to have substantial impact on drug expenditures in 2011. From 2008 to 2009, total U.S. drug expenditures increased by 5.2%, with total spending rising from $284.8 billion to $299.5 billion. Growth in drug expenditures in clinics grew by 5.1% from 2008 to 2009. Hospital drug expenditures increased at the moderate rate of 2.8% from 2008 to 2009; through the first nine months of 2010, hospital drug expenditures increased by only 0.8% compared with the same period in 2009. Conclusion. For 2011, we project a 3-5% increase in drug expenditures in outpatient settings, a 4-6% increase in expenditures for clinic-administered drugs, and a 1-3% increase in hospital drug expenditures.
引用
收藏
页码:921 / 932
页数:12
相关论文
共 35 条
[21]   Physicians versus Hospitals as Leaders of Accountable Care Organizations. [J].
Kocher, Robert ;
Sahni, Nikhil R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (27) :2579-2582
[22]   Me-too products - Friend or foe? [J].
Lee, TH .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (03) :211-212
[23]   Health Care Reform and Cost Control [J].
Orszag, Peter R. ;
Emanuel, Ezekiel J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (07) :601-603
[24]  
Rogers E., 1995, Diffusion of innovations
[25]   Clinical comparability and European biosimilar regulations [J].
Schellekens, Huub ;
Moors, Ellen .
NATURE BIOTECHNOLOGY, 2010, 28 (01) :28-31
[26]   Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Current Clinical Evidence and Future Developments [J].
Schirmer, Stephan H. ;
Baumhaekel, Magnus ;
Neuberger, Hans-Ruprecht ;
Hohnloser, Stefan H. ;
van Gelder, Isabelle C. ;
Lip, Gregory Y. H. ;
Boehm, Michael .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (25) :2067-2076
[27]   National Health Spending Projections: The Estimated Impact Of Reform Through 2019 [J].
Sisko, Andrea M. ;
Truffer, Christopher J. ;
Keehan, Sean P. ;
Poisal, John A. ;
Clemens, M. Kent ;
Madison, Andrew J. .
HEALTH AFFAIRS, 2010, 29 (10) :1933-1941
[28]   Risk evaluation and mitigation strategies: Challenges and opportunities for health-system pharmacists [J].
Stubbings, JoAnn ;
Joshi, Rutu A. ;
Hoffman, James M. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (18) :1547-1554
[29]  
THOMPSON CA, 2010, AM J HEALTH-SYST PH, V67, P1488
[30]   FDA approves first generic enoxaparin product [J].
Thompson, Cheryl A. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (18) :1486-+